97155 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Sub-classes:IMMUNOGLOBULIN VARIABLE DOMAINS
#2COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
#3ANTIBODIES TARGETING C-KIT AND/OR SIGLEC AND USES THEREOF
#4COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES WITH ANTI-CLL-1 DIRECTED THERAPY
#5ANTI-IL-27 ANTIBODIES AND USES THEREOF
#6METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS
#7ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN AND USE THEROF
#8Safety Kill Switches for Engineered Cells Carrying Synthetic Chromosomes
#9COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS
#10USE OF ANTI-MCP1 NEUTRALIZING ANTIBODY IN PREPARING MEDICAMENT FOR TREATING SYSTEMIC INFLAMMATION CAUSED BY NEURODEGENERATIVE DISEASES
#11ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
#12Therapeutic Antibodies Against Osteopontin
#13ADENO-ASSOCIATED VIRUS (AAV) DELIVERY OF ANTI-FAM19A5 ANTIBODIES
#14Preventative Agent or Therapeutic Agent for Amyotrophic Lateral Sclerosis, Parkinson's Disease, Huntington's Disease, Spinocerebellar Ataxia, Aging-Related Degenerative or Neurological Disease, Brain Aging, or Diseases Associated With Brain Aging
#15METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS
#16HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
#17ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
#18METHODS FOR TREATING DISEASE USING PSMP ANTAGONISTS
#19TREATMENT OF METABOLIC SYNDROME AND ASSOCIATED MORBIDITIES USING INTESTINAL TH17 CELLS OR INTESTINAL TH17 CELL-DERIVED MOLECULES
#20ANTIBODIES AGAINST CHEMOKINES, METHOD FOR IDENTIFYING SAID ANTIBODIES AND USES THEREOF
#21USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF GLAUCOMA
#22USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS
#23THERAPEUTIC MODULATION OF GENES IN MYELOID LINEAGE CELLS AND USES THEREOF IN OPHTHALMOLOGY
#24Pharmaceutical Composition for Preventing or Treating Sjogren's Syndrome Comprising Anti-SEMA4D Blocking Antibody as Active Ingredient
#25PHARMACEUTICAL USE OF FAM19A5 INVOLVED IN REGULATING GLIOGENESIS
#26Atomic Description of Immune Complex that Causes Heparin-Induced Thrombocytopenia
#27ANTI-AGE ANTIBODIES FOR TREATING NEURODEGENERATIVE DISORDERS
#28Stabilised Protein Solutions
#29ANTIBODY FRAGMENT SPECIFIC TO C-KIT POSITIVE TUMORS
#30Compositions For and Methods of Preventing Metastases
#31COMPOSITIONS, METHODS AND USES OF ALPHA 1-ANTITRYPSIN FOR TREATMENT OF GRAFT VERSUS HOST DISEASE
#32TREATMENT OF BRAIN METASTASIS
#33LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
#34CONJUGATED C1 ESTERASE INHIBITOR AND USES THEREOF
#35CCL4 ANTAGONIST FOR INHIBITING VASCULAR AGING
#36ANTIGEN BINDING PROTEINS CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN
#37ANTI-HUMAN CXCL1 ANTIBODY
#38METHOD FOR PREVENTING OR TREATING SKIN AGING OR INFLAMMATION OR INCREASING A CONTENT OF COLLAGEN
#39TRIPLE COMBINATION ANTIBODY THERAPIES
#40SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#41IMPROVED Fc SILENCED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
#42STABLE ANTI-OSMR ANTIBODY FORMULATION
#43METHOD FOR MODULATING APPETITE
#44ANTIBODIES AGAINST S100A8 AND S100A9, HETERODIMER OF S100A8 AND S100A9, DETECTION KIT AND USE OF THE ANTIBODIES, HETERODIMER AND DETECTION KIT
#45Anti-S100A4 humanized antibodies, uses and methods
#46ANTI-CLL-1 ANTIBODIES AND USES THEREOF
#47METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS
#48METHOD FOR IMPROVING WOUND HEALING
#49PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY
#50CXCR3 LIGAND HAVING ENHANCED CXCR3-EXPRESSING CELL MIGRATION ACTIVITY
#51USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
#52USE OF CCL7 ANTAGONISTS FOR THE PREVENTION OR TREATMENT OF DIABETIC KIDNEY DISEASE
#53METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS
#54COMPOSITION, METHOD AND KIT FOR PATHOLOGY
#55STEM CELL FACTOR INHIBITOR
#56INTERLEUKIN 5 BINDING PROTEIN DOSAGE REGIMEN FOR USE IN TREATING POLYANGIITIS, HYPEREOSINOPHILIC SYNDROME, CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP), OR CHRONIC RHINOSINUSITIS WITHOUT NASAL POLYPS (CRSSNP)
#57TREATMENT OF ASTHMA WITH ANTI-TSL P ANTIBODY
#58METHODS OF DETECTING AND TREATING CEREBRAL ANEURYSMS
#59IMMUNOGLOBULINS AND USES THEREOF
#60KIDNEY TARGETED IMMUNOTOLERANCE
#61PRODUCTS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPARIN-INDUCED THROMBOCYTOPENIA
#62PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVA
#63METHOD FOR TREATING A PERIOHERAL ARTERIAL DISEASE
#64ANTI-PDGF-B ANTIBODIES AND PHARMACEUTICAL COMPOSITION THEREOF
#65Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity
#66ANTIBODIES TARGETING XCL1 AND METHODS OF USING THE SAME
#67Methods of Treating Conditions Associated with Leaky Gut Barrier
#68COMPOSITION FOR TREATING OR PREVENTING IMMUNOLOGICAL ABNORMAL INFLAMMATORY DISEASES
#69Methods of Improving Recovery After Lung Resection
#70OPTIMIZED ANTI-TL1A ANTIBODIES
#71ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
#72BISPECIFIC ANTI-CCL2 ANTIBODIES
#73SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
#74SYNTHETIC IMMUNO-SUPPRESSIVE CELLS AND METHODS OF USE THEREOF
#75ANTIBODY TO CXCL12 AND COMPOSITION COMPRISING SAME FOR TREATMENT OF HAIR LOSS
#76HUMAN CXCLI6 ANTIBODIES AND THE USE THEREOF
#77TREATMENT OF EOSINOPHIL OR MAST CELL RELATED DISORDERS
#78ANTI-CXCR5 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#79ANTIGEN-BINDING MOLECULE PROMOTING DISAPPEARANCE OF ANTIGENS HAVING PLURALITY OF BIOLOGICAL ACTIVITIES
#80Antibody capable of binding to thymic stromal lymphopoietin and use thereof
#81Atomic description of immune complex that causes heparin-induced thrombocytopenia
#82BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS
#83STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF
#84USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF GLAUCOMA
#85PHARMACEUTICAL USE OF FAM19A5 INVOLVED IN REGULATING GLIOGENESIS
#86Treatment Of Kidney Diseases With A Combination of Angiopoietin Like 3 (ANGPTL3) Inhibitors And Solute Carrier Family 5 Member 2 (SLC5A2) Inhibitors
#87TREATMENT OF SMC MEDIATED DISEASE
#88ANTI-S100A8/A9 ANTIBODY AND USE THEREOF
#89INFLAMMASOME ANTIBODY COMPOSITON AND METHOD FOR TREATING NEUROLOGIC DISORDER
#90ANTIBODIES AND ASSAYS FOR CCL14
#91CHEMERIN INHIBITORS AND USES THEREOF FOR TREATING KIDNEY CANCER
#92Thermoresponsive or Shear-Thinning Injectable Gel Compositions for Treatment of Arthritis
#93Bispecific anti-CCL2 antibodies
#94HUMANIZED CC CHEMOKINE RECEPTOR 4 (CCR4) ANTIBODIES AND METHODS OF USE THEREOF
#95METHODS OF PRODUCING MIXED CHIMERISM AFTER A SOLID ORGAN TRANSPLANT
#96DIFFERENTIAL DIAGNOSIS OF ECZEMA AND PSORIASIS
#97OSTEOPONTIN MONOCLONAL ANTIBODIES FOR CANCER AND OSTEOPOROSIS IMMUNOTHERAPY
#98COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
#99BISPECIFIC ANTI-CCL2 ANTIBODIES
#100ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF BLOCKING THE INTERACTION BETWEEN SCF AND c-KIT
#101CXCL10 BINDING PROTEINS AND USES THEREOF
#102Anti-S100A4 Humanized Antibodies, Uses and Methods
#103Anti-Jagged Antibodies and Methods of Use
#104Agent for Preventing or Treating Frontotemporal Lobar Degeneration
#105CYTOSOLIC PROTEIN TARGETING DEUBIQUITINASES AND METHODS OF USE
#106PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITIS COMPRISING IL-31 ANTAGONIST AS ACTIVE INGREDIENT
#107COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION
#108ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE
#109CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
#110EGG, FERTILIZED EGG, OR EMBRYO QUALITY IMPROVING AGENT
#111METHODS OF TREATING SPONDYLOARTHRITIS OR SYMPTOMS THEREOF
#112PHARMACEUTICAL COMPOSITION COMPRISING ANTI-HUMAN TSLP RECEPTOR ANTIBODY
#113Liver-specific Wnt signal enhancing molecules and uses thereof
#114IMPROVED ANTI-oxMIF ANTIBODIES WITH REDUCED AGGREGATION POTENTIAL AND REDUCED HYDROPHOBICITY
#115ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
#116METHODS FOR TREATING OR PREVENTING HEADACHE DISORDERS
#117USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF NEUROPATHIC PAIN
#118USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING CANCERS
#119COMPOSITION COMPRISING CHEMOKINE INHIBITOR, COLONY STIMULATING FACTOR INHIBITOR, AND CANCER IMMUNOTHERAPY AGENT FOR PREVENTION OR TREATMENT OF CANCER AND COMBINATION THERAPY
#120ANTI-FAM19A5 ANTIBODIES AND USES THEREOF
#121HUMANIZED ANTI-EMAP II THERAPEUTIC ANTIBODIES
#122COMPOSITIONS AND METHODS FOR ANTIGEN IDENTIFICATION
#123COMPOSITIONS AND METHODS FOR PREVENTING ACUTE KIDNEY INJURY-INDUCED ACUTE LUNG INJURY (AKI-ALI)
#124COMBINATION THERAPIES FOR THE TREATMENT AND PREVENTION OF BIOFILMS
#125Fully humanized anti-platelet factor 4 antibodies that treat heparin-induced thrombocytopenia
#126CYTOKINE VARIANT ANTIBODIES AND METHODS OF USE
#127METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS
#128METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
#129METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY
#130Anti-S100A4 antibodies for the treatment of systemic sclerosis
#131CCL24 INHIBITORS IN THE TREATMENT OF COVID-19
#132OPTIMIZED ANTI-TL1A ANTIBODIES
#133Human Antibodies to GREM1
#134COMPOSITIONS COMPRISING BACTERIAL STRAINS
#135TARGETED THERAPY FOR THE TREATMENT & PREVENTION OF LIFE-THREATENING COMPLICATIONS OF INFECTION
#136Atomic description of immune complex that causes heparin-induced thrombocytopenia
#137PAN-ELR+ CXC CHEMOKINE ANTIBODIES FOR THE TREATMENT OF RESPIRATORY DISEASE
#138PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY PULMONARY DISEASE
#139Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition
#140COMBINED ANTI-CYTOKINE THERAPY TO REDUCE METASTATIC CANCER
#141MITIGATION AND REVERSAL OF INTESTINAL FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION
#142METHODS OF TREATING AN INFLAMMATORY OR OBSTRUCTIVE AIRWAY DISEASE USING ANTI-TSLP ANTIBODY
#143FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS
#144Triple combination antibody therapies
#145MULTISPECIFIC ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
#146TREATING IMMUNE PLATELET DISORDERS USING ANTIGEN-BINDING FRAGMENTS
#147CXCL10 binding proteins and compositions thereof
#148ANTI-oxMIF/ANTI-CD3 BISPECIFIC ANTIBODY CONSTRUCTS
#149Human monoclonal antibody binding specifically to human HMGB1, and pharmaceutical composition for treating or preventing Alzheimer's disease containing said human monoclonal antibody
#150ANTI-GDF15 ANTIBODY
#151METHOD FOR TREATING GASTRIC CANCER BY BLOCKING CCL28 CHEMOTACTIC PATHWAY
#152ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF
#153Stabilised Protein Solutions
#154COMPOSITIONS AND METHODS OF TREATING THROMBOSIS
#155Splicing modulator antibody-drug conjugates and methods of use
#156Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
#157PROGNOSIS PREDICTION METHOD OF IDIOPATHIC PULMONARY FIBROSIS
#158ANTIBODIES AND ASSAYS FOR CCL14
#159ENGINEERED IMMUNOGLOBULINS WITH ALTERED FCRN BINDING
#160ANTI-CCL17 ANTIBODIES
#161ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF
#162ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN AND USE THEREOF
#163METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
#164METHODS FOR IDENTIFYING AND TREATING URINARY TRACT INFECTIONS
#165IMMUNOGLOBULIN VARIABLE DOMAINS
#166IMMUNOGLOBULIN VARIABLE DOMAINS
#167IMMUNE EFFECTOR CELL FOR CO-EXPRESSING CHEMOKINE RECEPTOR
#168ANTI-INFLAMMATORY PEPTIDES, PHARMACEUTICAL COMPOSITION CONTAINING SUCH PEPTIDES, AND USES THEREOF
#169ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF IN RENAL DISEASE
#170Therapeutic Antibodies Against Osteopontin
#171Compositions and methods for treatment of diseases involving CXCL1 function
#172METHODS FOR IDENTIFYING AND TREATING HIGH-PLASTICITY CELL STATE DRIVING TUMOR PROGRESSION IN LUNG CANCER
#173ANTI-IL-27 ANTIBODIES AND USES THEREOF
#174CHIMERIC PROTEIN EXPRESSING T-CELLS
#175COMBINATION THERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASES
#176Immunoglobulin variable domains
#177Anti-PDGF-B antibodies and pharmaceutical composition thereof
#178Method of treating aging-associated cognitive impairment by reducing CCR3
#179BIOMARKER FOR RHEUMATOID ARTHRITIS TREATMENT
#180THERAPEUTIC AGENT FOR UROLOGICAL CANCER WHICH IS CHARACTERIZED BY BEING ADMINISTERED WITH IL-6 INHIBITOR AND CCR2 INHIBITOR IN COMBINATION
#181Methods for preventing and treating or diagnosing coronavirus infection
#182ION CONCENTRATION-DEPENDENT BINDING MOLECULE LIBRARY
#183NET STABILIZATION AS A THERAPY FOR SEPSIS
#184METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
#185COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION
#186COMBINATION IMMUNOTHERAPY
#187Methods and compositions for treating virus-associated inflammation
#188METHODS OF TREATMENT USING AN INTERFERON GAMMA INHIBITOR
#189ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES AND METHOD OF USE THEREOF
#190METHODS FOR TREATING TRAUMATIC BRAIN INJURY
#191TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A S1P MODULATOR
#192Immunoglobulin variable domains
#193Immunoglobulin variable domains
#194ANTIBODY-DRUG CONJUGATES AND USE OF ANTIBODIES FOR DRUG DELIVERY
#195Activatable anti-VEGF scFv
#196PERIOSTEAL SKELETAL STEM CELLS IN BONE REPAIR
#197Use of anti-FAM19A5 antibodies for treating fibrosis
#198METHODS FOR TREATING DISEASE USING PSMP ANTAGONISTS
#199Methods for preventing and treating or diagnosing coronavirus infection
#200Use of anti-FAM19A5 antibodies for treating atherosclerosis
#201Stable Anti-OSMR Antibody Formulation
#202Treatment of eosinophil or mast cell related disorders
#203Human IL-23 antigen binding proteins
#204Method of promoting wound healing by inhibiting CCR3
#205Methods of Inhibiting Metastasis in Cancer
#206Pharmaceutical composition comprising anti-human TSLP receptor antibody
#207STEM CELL FACTOR INHIBITOR
#208PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION
#209ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
#210Adeno-associated virus (AAV) delivery of anti-FAM19A5 antibodies
#211ANTI-EMAP II ANTIBODY AND USE THEREOF
#212Use of CXCL13 binding molecules to promote peripheral nerve regeneration
#213Compositions And Methods For Treating Cancer
#214Treatment and Prevention of Cardiovascular Disease
#215USE OF ANTI-FAM19A5 ANTIBODIES
#216PAN-ELR+ CXC chemokine antibodies for the treatment of hidradenitis suppurativa
#217METHOD FOR MODULATING APPETITE
#218MONOCYTE MODULATION AND CONTROL OF TUMOR METASTASIS
#219Methods and Compositions for Treating Neurodegeneration and Fibrosis
#220METHODS FOR MODULATING INFLAMMASOME ACTIVITY AND INFLAMMATION IN THE LUNG
#221MULTISPECIFIC ANTIBODIES
#222COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
#223Composition for prophylaxis or treatment of IL-8 related diseases
#224Compositions and methods for treatment of diseases involving CXCL1 function
#225Splicing modulator antibody-drug conjugates and methods of use
#226FILOVIRUS ANTIBODY
#227Anti-CXCL13 antibodies for treating autoimmune diseases and cancer
#228COMPOSITIONS AND METHODS FOR TREATING INFLAMMASOME RELATED DISEASES OR CONDITIONS
#229HUMAN ANTIBODIES AGAINST EOTAXIN AND THEIR USE
#230COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
#231Humanized anti-S100A9 antibody and uses thereof
#232Immunoglobulin variable domains
#233Immunoglobulin variable domains
#234Immunoglobulin variable domains
#235Gremlin-1 antagonist for the prevention and treatment of cancer
#236Multiple specificity binders of CXC chemokines
#237NOVEL ANTIGEN BINDING DIMER-COMPLEXES, METHODS OF MAKING/AVOIDING AND USES THEREOF
#238Human IL-23 Antigen Binding Proteins
#239CCL24 as a diagnostic and therapeutic target for breast cancer
#240METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES
#241Ligand-binding molecule having adjustable ligand-binding activity
#242Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#243METHODS AND MATERIALS FOR GENE EDITING
#244METHOD FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES
#245Endogenous Labelling of Extracellular Vesicles
#246Dual-targeting antibody targeting SCF and galectin-1 and use thereof
#247Bispecific anti-CCL2 antibodies
#248Osteopontin monoclonal antibodies
#249COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS
#250Treatment of brain cancers using central nervous system mediated gene transfer of monoclonal antibodies
#251REFRACTORY ASTHMA PROPHYLACTIC/THERAPEUTIC AGENT SCREENING METHOD, AND REFRACTORY ASTHMA PROPHYLACTIC/THERAPEUTIC AGENT
#252Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#253LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS OF TREATING SYSTEMIC LUPUS ERYTHEMATOSUS
#254Methods of Treating Conditions Associated with Leaky Gut Barrier
#255Methods for treatment of cancer comprising TIGIT-binding agents
#256Anti-CXCR5 antibodies and compositions and uses thereof
#257Splicing modulator antibody-drug conjugates and methods of use
#258Egg, fertilized egg, or embryo quality improving agent
#259Immunoglobulins and uses thereof
#260ANTI-CLEVER-1 AGENTS FOR CONTROLLING LYSOSOMAL VATPASE PROTON PUMPS TO INCREASE LYSOSOMAL PH-VALUE AND THE CROSS-PRESENTATION OF DIGESTED MATTER
#261Anti-CXCL13 antibodies and methods of using the same
#262Immunoglobulin variable domains
#263Anti-GM-CSF antibodies and uses thereof
#264Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
#265BLOCKADE OF CCL18 SIGNALING VIA CCR6 AS A THERAPEUTIC OPTION IN FIBROTIC DISEASES AND CANCER
#266Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
#267Composition, method and kit for pathology
#268Antibodies and assays for CCL14
#269Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
#270Anti-S100A8/A9 antibody and use thereof
#271TREATMENT OF ASTHMA WITH ANTI-TSLP ANTIBODY
#272Treatment and prevention of cardiovascular disease
#273Methods of treating inflammation associated airway diseases and viral infections
#274MODULATION OF P62 AND STING ACTIVITY
#275USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORS
#276HUMAN IL-23 ANTIGEN BINDING PROTEINS
#277ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
#278Anti-CCL17 antibodies
#279METHODS OF PURIFYING MONOMERIC MONOCLONAL ANTIBODIES
#280Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
#281Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)
#282Anti-CXCL13 antibodies
#283Immunoglobulins and uses thereof
#284Method of treating psoriatic arthritis with increased interval dosing of anti-IL12/23 antibody
#285Anti-jagged antibodies and methods of use
#286METHODS AND KITS FOR ANALYSIS OF HMGB1 ISOFORMS
#287Porous affinity hydrogel particles for reducing the bioavailability of selected biological molecules
#288Methods for treating lung inflammation with an anti-ASC antibody
#289THYMIC STROMAL LYMPHOPOIETIN (TSLP)-BINDING MOLECULES AND METHODS OF USING THE MOLECULES
#290Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment and diagnosis of mood disorders
#291Anti-CCL8 antibodies and uses thereof
#292Anti-FAM19A5 antibodies and uses thereof
#293Anti-human migration stimulating factor (MSF) and uses thereof
#294Compositions and methods for treatment of diseases involving CXCL1 function
#295Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#296Pharmaceutical use of FAM19A5 involved in regulating gliogenesis
#297Optimized anti-TL1A antibodies
#298THERAPEUTIC ANTIBODIES AND USES THEREOF
#299Immunoglobulin variable domains
#300Use of anti-FAM19A5 antibodies for treating cancers